clinical trial · NCT05100134
Managed Access Programs for LDK378, Ceritinib
Anaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC)ceritinib
brief summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.
started
—
primary completion
—
completion
—
last updated
Apr 1, 2026
detailed description
CLDK378A2401 - No longer available - Managed Access Program (MAP) to provide access to Ceritinib, for ALK Positive Tumors.
CLDK378A2402 - No longer available - An open-label, multi-center, Expanded Treatment Protocol (ETP) of oral LDK378 in adult patients with non-small cell lung cancer (NSCLC) characterized by ALK positivity.
CLDK378A2003M - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CLDK378A2003M to provide access to LDK378 (ceritinib), for ALK-Positive Tumor Pediatric Patients.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol